| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Many cancer cells also exert resistance to the action of anti-cancer agents because they reprogram metabolism in a glycolytic-dominant manner and respond to adverse environments. The glucose analog 2-deoxyglucose (2DG) not only inhibits glycolysis and suppresses the growth of cancer cells, but also enhances the action of drugs such as anticancer agents. In the present study, we found that 2DG synergistically enhanced the action of cisplatin or metformin on pancreatic cancer cells. It was also found that the combination of 2DG and metabolite suppressed the action of 2DG on cells. It is expected that the cancer treatment will be further advanced by further understanding the action of 2DG.
|
